Publication
CD84 expression stratifies venetoclax response and reveals a targetable vulnerability in resistant acute myeloid leukemia.
Xuemei Wang, Xiangjie Lin, Tianyi Chen, Yi Chen, Huafeng Wang, Yinghui Zhu
Experimental hematology & oncologySep 7, 2026PMID 42706583doi:10.1186/s40164-026-00830-z LetterpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260908-000002
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Venetoclax-based regimens have become increasingly integrated into the therapeutic landscape of acute myeloid leukemia (AML), yet primary resistance and relapses remain major barriers to durable benefits. Building on our previous discovery of CD84 as a critical survivor and redox regulator in AML,…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerLeukemiadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.